Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26742225 | 0.91 | KDM1A (0.36) | NPY1RVCPHRH3SLC6A4SLC6A3 | |
| SCHEMBL26742218 | 0.88 | HRH1 (0.39) | NPY1RHRH3SLC6A4MAOBMAOA | |
| SCHEMBL26742221 | 0.88 | HRH3 (0.37) | HRH3SLC6A4SLC6A3 | |
| SCHEMBL26706166 | 0.85 | CYP2D6 (0.36) | NPY1RVCPHRH3SLC6A4SLC6A3 | |
| SCHEMBL26753580 | 0.85 | SLC6A4 (0.39) | NPY1RHRH3SLC6A4SLC6A3 | |
| SCHEMBL12448061 | 0.84 | HRH3 (0.40) | NPY1RHRH3 | |
| SCHEMBL12448063 | 0.84 | MAOB (0.43) | HRH3SLC6A4MAOBMAOA | |
| SCHEMBL26752141 | 0.84 | HRH1 (0.38) | HRH3SLC6A4MAOBMAOA | |
| SCHEMBL26743216 | 0.83 | HRH3 (0.45) | HRH3SLC6A4SLC6A3 | |
| SCHEMBL20046477 | 0.82 | VCP (0.44) | VCPHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | NPY1R 2559/4885VCP 1882/4885HRH3 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.